Paloxi ODT 0.5 mg (Dispersible Tablet)

Unit Price: ৳ 22.00 (3 x 10: ৳ 660.00)

Strip Price: ৳ 220.00

Medicine Details

Category	Details
Generic	Palonosetron
Company	Beacon pharmaceuticals plc
Also available as	Paloxi 05 mg capsule Paloxi 0075 mg injection Paloxi 025 mg injection Paloxi 05 mg tablet

Paloxi ODT is indicated for acute and delayed nausea and vomiting, uncontrolled nausea and vomiting, chemotherapy-induced nausea and vomiting, delayed CINV, radiotherapy-induced nausea and vomiting, post-operative & post-discharge nausea and vomiting. It works by blocking the actions of serotonin, associated with nausea and vomiting, at 5-HT3 receptors. Paloxi ODT has a longer half-life (40 hours) and a greater 5-HT3 receptor binding affinity.

Palonosetron is a 5-HT3 receptor antagonist with a strong binding affinity for this receptor and little or no affinity for other receptors. It is thought that chemotherapeutic agents produce nausea and vomiting by releasing serotonin from the enterochromaffin cells of the small intestine and that the released serotonin then activates 5-HT3 receptors.

0.5 mg administered approximately 1 hour prior to the start of chemotherapy for adults
0.25 mg as a single IV dose administered over 30 seconds approximately 30 minutes before the start of chemotherapy for adults
A single IV dose of 0.25 mg administered over 30 seconds approximately 30 minutes before each week of radiation fraction for radiotherapy-induced nausea and vomiting in adults
A single IV dose of 0.075 mg administered over 10 seconds immediately before induction of anesthesia for post-operative nausea and vomiting in adults
A single IV dose at 20 mcg/kg body weight for children (1 month to 17 years), with a maximum dose of 1.5 mg

Safely administered with corticosteroids, analgesics, antiemetics/antinauseants, antispasmodics, and anticholinergic agents
No significant pharmacokinetic interactions with metoclopramide
Not an inhibitor of multiple CYP enzymes